[144] LIGAND PHARMACEUTICALS INC SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Ligand Pharmaceuticals, Inc. (LGNZZ): An insider filed to sell 10,000 shares of the company's common stock through Charles Schwab & Co., with an approximate aggregate market value of $1,685,000. The filing reports the shares were acquired in the open market on October 9, 2014 (payment dated October 1, 2014) and the proposed sale date is September 17, 2025 on NASDAQ. The filing states there were 19,596,560 shares outstanding, and no securities were sold by the filer in the past three months. The filer certifies no undisclosed material information is known.

Insights

Securities Analyst

TL;DR: Small insider sale relative to outstanding shares; likely routine liquidity rather than a material signal.

The proposed sale of 10,000 shares equals about 0.05% of the reported 19,596,560 shares outstanding, indicating this transaction is immaterial to market capitalization. The filing provides acquisition details (open market purchase in 2014) and shows no recent sales in the prior three months, which reduces the likelihood of an immediate trend of insider selling. From a market-impact perspective this Form 144 is informational and does not indicate company-level operational or financial change.

Corporate Governance Expert

TL;DR: Disclosure complies with Rule 144; the notice documents required representations and trading channel.

The Form 144 identifies the broker (Charles Schwab & Co.) and confirms the filer represents no undisclosed material adverse information. It includes acquisition and payment dates and notes no aggregated sales in the past three months. For governance oversight, the filing meets regulatory transparency requirements but does not signal governance concerns or insider pattern changes given the small size and age of acquisition.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Charles Schwab & Co 3000 Schwab Way Westlake TX 76262	10000	1685000.00	19596560	09/17/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	10/09/2014	Open Market Purchase	n/a			10000	10/01/2014	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did the Form 144 filed for Ligand Pharmaceuticals (LGNZZ) report?

The filing reports a proposed sale of 10,000 common shares via Charles Schwab & Co. with an aggregate market value of $1,685,000 and an approximate sale date of September 17, 2025.

How many shares of Ligand are outstanding according to the filing?

The filing states there are 19,596,560 shares outstanding.

When were the shares being sold acquired?

The shares were acquired by the filer in an open market purchase on October 9, 2014, with a payment date listed as October 1, 2014.

Does the Form 144 show any other sales by the filer in the past three months?

No. The filing explicitly states: Nothing to Report for securities sold during the past three months.

Which broker is handling the proposed sale?

The broker named in the filing is Charles Schwab & Co., 3000 Schwab Way, Westlake TX 76262 and the sale is to occur on NASDAQ.